KLA
KLA Corporation
Key figures
Period Jul 2025 to Jun 2026ConsolidatedU.S. GAAP
RevenueDisclosed
US$13.6B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
35.4%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★★★★☆position among all companies
10.2%
Capital efficiency
★★★★★position among all companies
76.1%
Revenue and profit
Performance, financial position and capital allocation
KLA
Recent performance trends
KLA
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$9.2 billion | US$10.5 billion | US$9.8 billion | US$12.2 billion | US$13.6 billion |
| Net income | US$3.3 billion | US$3.4 billion | US$2.8 billion | US$4.1 billion | US$4.8 billion |
| Total assets | US$12.6 billion | US$14.1 billion | US$15.4 billion | US$16.1 billion | US$18.0 billion |
| Shareholders' equity | US$1.4 billion | US$2.9 billion | US$3.4 billion | US$4.7 billion | US$6.3 billion |
| Net cash provided by (used in) operating activities | US$3.3 billion | US$3.7 billion | US$3.3 billion | US$4.1 billion | US$4.1 billion |
| Net cash provided by (used in) investing activities | US$-0.9 billion | US$-0.5 billion | US$-1.5 billion | US$-0.2 billion | US$-1.2 billion |
| Net cash provided by (used in) financing activities | US$-2.3 billion | US$-2.8 billion | US$-1.8 billion | US$-3.8 billion | US$-3.4 billion |
| Cash and cash equivalents | US$1.6 billion | US$1.9 billion | US$2.0 billion | US$2.1 billion | US$1.6 billion |
Revenue scale in the same industry
KLA
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 6 companies
- 10 GE Healthcare TechnologiesFY Dec 2025 US$20.6B
- 11 Boston ScientificFY Dec 2025 US$20.1B
- 12 KLAThis companyFY Jun 2026 US$13.6B
- 13 Baxter InternationalFY Dec 2025 US$11.2B
- 14 Intuitive SurgicalFY Dec 2025 US$10.1B
- … 29 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.4 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$1.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-3.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-1.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$4.1 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.4 billion | Consolidated | Disclosed |
| Dividends paid | US$1.1 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$6.3 billion | Consolidated | Disclosed |
| Net assets | US$6.3 billion | Consolidated | Disclosed |
| Net sales | US$13.6 billion | Consolidated | Disclosed |
| Net income | US$4.8 billion | Consolidated | Disclosed |
| Total assets | US$18.0 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$2.3 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 35.4% | Consolidated | Calculated |
| Net margin | 35.6% | Consolidated | Calculated |
| Return on equity | 76.1% | Consolidated | Calculated |